Standigm
Employs deep learning workflows to streamline early-stage drug discovery projects.
What they do
Standigm develops workflow AI products that automate drug discovery from target identification to lead optimization. Pharmaceutical developers use the company's proprietary platforms, Standigm ASK and Standigm BEST, to rapidly generate novel molecular structures and identify repurposing candidates.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series C+
- Headquarters
- Seoul, South Korea
- Region
- Asia-Pacific
- Founded
- 2015
- Total funding
- $68M raised
Notable investors: Kakao Ventures, SoftBank Ventures Asia, LB Investment, Atinum Investment.